Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

PURPOSE: Interleukin-15 (IL-15) has significant potential in cancer immunotherapy as an activator of antitumor CD8 T and natural killer (NK) cells. The primary objectives of this trial were to determine safety, adverse event profile, dose-limiting toxicity, and maximum-tolerated dose of recombinant...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Conlon, Kevin C., Lugli, Enrico, Welles, Hugh C., Rosenberg, Steven A., Fojo, Antonio Tito, Morris, John C., Fleisher, Thomas A., Dubois, Sigrid P., Perera, Liyanage P., Stewart, Donn M., Goldman, Carolyn K., Bryant, Bonita R., Decker, Jean M., Chen, Jing, Worthy, Tat'Yana A., Figg, William D., Peer, Cody J., Sneller, Michael C., Lane, H. Clifford, Yovandich, Jason L., Creekmore, Stephen P., Roederer, Mario, Waldmann, Thomas A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2015
Aiheet:
Original Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4268254/
https://ncbi.nlm.nih.gov/pubmed/25403209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.3329
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia